Analysis: Sustained Eczema and Psoriasis Remission Achieved with Dupilumab

Key Takeaways 

• Dupilumab achieved clinical remission in 33.1% of pediatric patients with moderate-to-severe atopic dermatitis, with sustained benefits observed off-treatment for up to six months.
• More than half of patients who achieved remission sustained it for at least three months after discontinuing dupilumab.

A new study highlights the potential of dupilumab to deliver sustained remission in children with moderate-to-severe atopic dermatitis (AD).

The findings, presented as a poster at the 2025 Masterclasses in Dermatology conference in Sarasota, stem from the LIBERTY AD PED OLE study, an ongoing open-label extension that included 163 pediatric patients with AD aged 6 months to 5 years. The study researchers defined clinical remission as an Investigator’s Global Assessment (IGA) score of 0/1 (clear or almost clear skin) maintained for at least 12 weeks.

According to the results, 33.1% of participants achieved clinical remission. Of those, 53.7% sustained remission for 3 months after discontinuing dupilumab, and 29.6% maintained remission for 6 months off-treatment. The authors noted that these findings underscore the potential of dupilumab to modify the disease course, providing durable relief even after treatment cessation.

"Longer term observations will elucidate whether these findings are durable, suggesting disease course modification," the researchers added. 

Source: Sigfried E, Beiber T, Paller A, et al. Clinical Remission and Off-Treatment Remission in Infants and Preschoolers With Moderate-To-Severe Atopic Dermatitis Treated With Dupilumab: Preliminary Data From an Open-Label Extension Study. Presented at: Masterclasses in Dermatology, Sarasota, FL, USA; February 20–23, 2025